BTIG raised the firm’s price target on Insulet (PODD) to $310 from $300 and keeps a Buy rating on the shares after its Q4 earnings beat. The ...

BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...

Digital Services Analyst Fuller holds a meeting with management in Boston on February 24 hosted by BTIG. Published first on TheFly – the ultimate ...

BTIG lowered the firm’s price target on NeoGenomics (NEO) to $17 from $18 and keeps a Buy rating on the shares. Q4 results came in light “at an ...

When we spoke three years ago, your research was focused on the shopping center, net lease and health care subsectors. Is there anything new or different about your coverage universe here in 2025? Mr.

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth.